IDEAYA and Servier Launch Phase 3 Trial for Uveal Melanoma Adjuvant Therapy
Event summary
- IDEAYA Biosciences and Servier dosed the first patient in the OptimUM-11 Phase 3 trial evaluating darovasertib and crizotinib as adjuvant therapy for high-risk uveal melanoma.
- The global trial aims to enroll 450 patients, with primary endpoint being relapse-free survival.
- IDEAYA retains U.S. rights to darovasertib, while Servier holds rights outside the U.S.
- IDEAYA expects to complete NDA submission for darovasertib in metastatic uveal melanoma in the second half of 2026.
The big picture
The launch of the OptimUM-11 trial represents a strategic push to address the significant unmet need in adjuvant therapy for uveal melanoma, a rare and aggressive cancer with limited treatment options. IDEAYA's collaboration with Servier underscores the importance of global partnerships in advancing precision oncology therapies. The trial's success could position darovasertib as a key player in the uveal melanoma treatment landscape, potentially expanding its use across different stages of the disease.
What we're watching
- Clinical Success
- Whether the darovasertib and crizotinib combination can demonstrate efficacy in delaying or preventing metastatic recurrence in uveal melanoma.
- Regulatory Pathway
- The pace at which IDEAYA can secure FDA approval for darovasertib, given its multiple designations and ongoing submissions.
- Commercial Strategy
- How IDEAYA and Servier will navigate their shared development costs and commercial rights in different regions.